The agreement will combine the SIBCB’s research expertise in generating potential new drug targets, with MRC Technology’s experience in further developing early stage research for pharmaceutical application and commercialization. The focus of the collaboration is to fast track innovative drugable targets to create potent and selective novel therapeutics.
“SIBCB is one of the world’s leading academic research institutions and the initiative reflects our joint commitment to delivering drugs for the treatment of diseases of global significance. The collaboration gives us a strong partner in China and access to potential new targets to further develop into drug therapies,” said Dave Tapolczay, CEO of MRC Techology.
Supporting technology transfer and IP management efforts, MRC Technology set up its drug discovery laboratories in order to bridge the gap between innovative, early stage academic research and the development of intellectual property suitable for licensing to industry for further development and commercialization. De-risking novel targets by providing proof of concept and pharma-quality data packages fulfils a clear need in the drug discovery process. The collaboration opens the MRC Technology laboratories up to a new source of targets from SIBCB researchers.
